BTG.L on London Stock Exchange

27 Nov 2014
Price Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for BTG.L


BTG plc is an international specialist healthcare company. The Company is focused on three business areas: Specialty Pharmaceuticals, Interventional Medicine and Licensing & Biotechnology. Its focus within Specialty Pharmaceuticals is on antidote products that are used within hospitals. Its interventional medicine products are... (more)


Beta: 0.37
Market Cap (Mil.): £2,902.62
Shares Outstanding (Mil.): 362.83
Dividend: --
Yield (%): --


  BTG.L Industry Sector
P/E (TTM): 73.56 37.83 38.74
EPS (TTM): 0.11 -- --
ROI: 6.13 17.93 17.27
ROE: 7.14 18.73 18.18
Search Stocks

BTG says long-awaited varicose vein treatment has positive debut

Nov 11 - British drugs company BTG said it had started to roll out its varicose vein treatment to a positive response in the United States, as it said revenue for the year would be at the top end of forecasts.

11 Nov 2014

BRIEF-BTG posts rise in H1 profit, sees full-year revenue at top end

* Operating profit increased to £42.8m (h1 13/14: £25.0m)

11 Nov 2014

BRIEF-BTG to supply DC Bead, Bead Block directly to doctors in Europe

* To supply DC Bead and Bead Block directly to physicians in Europe from 1 April 2015

13 Oct 2014

BRIEF-BTG settles Crofab patent litigation case against Bioclon, RDT

* BTG would allow Bioclon to begin selling crotalid antivenom relying on BTG's 414 patent from October 2018

10 Oct 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Reuters Investment Profile
Provider: Peel Hunt

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks